Anne Wojcicki, founder of 23andMe, has successfully repurchased the genetic testing firm out of bankruptcy through her non-profit TTAM for $305 million, surpassing a prior winning bid from Regeneron. The deal, which excludes the company’s liabilities, may ease public concerns over genetic data transfers, given Wojcicki’s continued leadership. The acquisition still requires court approval, while lawsuits related to a 2023 data breach remain unresolved. The company’s shares have surged on recovery hopes. -Thinking of buying a Starlink? Use my link to support the show. -Get a United Chase Card and 10,000 miles, you are supporting GNC Travel with your signup! Subscribe to the Newsletter. Join the Chat @ GeekNews.Chat Email Todd or follow him on Facebook. Like and Follow Geek News Central’s Facebook Page. Download the Audio Show File New YouTube Channel – Beyond the Office Support my Show Sponsor: Best Godaddy Promo Codes $11.99 – For a New Domain Name cjcfs3geek $6.99 a month Economy Hosting (Free domain, professional email, and SSL certificate for the 1st year.) Promo Code: cjcgeek1h $12.99 a month Managed WordPress Hosting (Free domain, professional email, and SSL certificate for the 1st year.) Promo Code: cjcgeek1w Support the show by becoming a Geek News Central Insider Full Summary: In this episode titled “Anne Wojcicki regains control of 23andMe,” Todd Cochrane discusses the lead story about Annie Wojcicki, who successfully repurchased the genetic testing company 23andMe out of bankruptcy for $305 million through her nonprofit, ITAM. This acquisition enables Wojcicki to retain leadership while excluding company liabilities, although it requires court approval amid unresolved lawsuits stemming from a 2023 data breach. Cochrane expresses relief that the acquisition was not taken over by a firm potentially interested in exploiting customer genetic data, given that he has never submitted his DNA to any testing firms. He elaborates on past controversies surrounding 23andMe, including legal issues that previously barred Wojcicki from bidding on her company. Cochrane highlights that Wojcicki is backed by a Fortune 500 firm, which enhances confidence about the future of 23andMe. Following th